About Uroplasty (NASDAQ:UPI)
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company's products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Industry, Sector and Symbol
Industry Medical Devices & Implants
SectorMedical Devices & Implants
Trailing P/E Ratio-4.06666666666667
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-87.33%
Return on Assets-60.82%
Uroplasty (NASDAQ:UPI) Frequently Asked Questions
What is Uroplasty's stock symbol?
Uroplasty trades on the NASDAQ under the ticker symbol "UPI."
How were Uroplasty's earnings last quarter?
Uroplasty, Inc. (NASDAQ:UPI) announced its quarterly earnings data on Thursday, January, 22nd. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.02. The medical device company had revenue of $6.67 million for the quarter, compared to analyst estimates of $6.89 million. Uroplasty had a negative return on equity of 87.33% and a negative net margin of 31.58%. View Uroplasty's Earnings History.
Who are some of Uroplasty's key competitors?
Some companies that are related to Uroplasty include PLx Pharma (PLXP), Alphatec (ATEC), bebe stores (BEBE), Support.com (SPRT), NXT-ID (NXTD), Intersections (INTX), Opiant Pharmaceuticals (OPNT), NetSol Technologies (NTWK), Presbia (LENS), Aehr Test Systems (AEHR), GWG (GWGH), Verenium (VRNM), Cardiome Pharma (CRME), Cancer Genetics (CGIX), Conifer (CNFR), pSivida (PSDV), Mid-Con Energy Partners (MCEP) and Manhattan Bridge Capital (LOAN).
How do I buy Uroplasty stock?
Shares of Uroplasty can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uroplasty's stock price today?
One share of Uroplasty stock can currently be purchased for approximately $1.22.
How big of a company is Uroplasty?
Uroplasty has a market capitalization of $27.68 million.
How can I contact Uroplasty?
Uroplasty's mailing address is 5420 Feltl Road, MINNETONKA, MN 55343, United States. The medical device company can be reached via phone at +1-952-4266140.
MarketBeat Community Rating for Uroplasty (UPI)MarketBeat's community ratings are surveys of what our community members think about Uroplasty and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Uroplasty (NASDAQ:UPI) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Uroplasty (NASDAQ:UPI) Earnings History and Estimates Chart
Uroplasty (NASDAQ UPI) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/22/2015||Q3||($0.04)||($0.06)||$6.89 million||$6.67 million||View||Listen|
|10/23/2014||Q2||($0.07)||($0.05)||$6.49 million||$6.46 million||View||Listen|
|7/24/2014||Q1||($0.05)||($0.10)||$6.35 million||$6.39 million||View||Listen|
|5/15/2014||Q4 13||($0.04)||($0.05)||$6.40 million||$6.36 million||View||N/A|
|1/23/2014||Q314||($0.04)||($0.03)||$6.13 million||$6.40 million||View||Listen|
|10/24/2013||Q214||($0.05)||($0.04)||$6.09 million||$6.00 million||View||Listen|
|8/1/2013||Q1 2014||($0.05)||($0.08)||$5.60 million||$5.84 million||View||N/A|
|5/30/2013||Q4 2013||($0.04)||($0.05)||$5.59 million||$5.54 million||View||Listen|
Uroplasty (NASDAQ:UPI) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Uroplasty (NASDAQ:UPI)
No dividend announcements for this company have been tracked by MarketBeat.com
Uroplasty (NASDAQ UPI) Insider Trading and Institutional Ownership History
Uroplasty (NASDAQ UPI) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/30/2015||Brett Reynolds||CFO||Buy||5,000||$1.32||$6,600.00|| |
|1/29/2015||Kevin H Roche||Director||Buy||50,000||$1.23||$61,500.00|| |
|1/29/2015||Robert Kill||CEO||Buy||25,000||$1.26||$31,500.00|| |
|7/30/2014||Kevin H Roche||Director||Buy||10,000||$2.45||$24,500.00|| |
|7/29/2014||Kevin H Roche||Director||Buy||9,000||$2.44||$21,960.00|| |
|6/3/2014||Kevin H Roche||Director||Buy||10,000||$2.97||$29,700.00|| |
|6/2/2014||Robert Kill||CEO||Buy||13,950||$2.95||$41,152.50|| |
|3/6/2014||Susan Hartjes Holman||VP||Sell||38,000||$3.98||$151,240.00||274,680|| |
|1/29/2014||Susan Hartjes Holman||SVP||Sell||52,500||$4.59||$240,975.00||312,680|| |
|12/11/2013||Robert Patrick Maxwell||Director||Sell||3,819||$2.70||$10,311.30||136,584|| |
|8/23/2013||Brett Reynolds||CFO||Buy||8,000||$2.99||$23,920.00||58,000|| |
|8/23/2013||James Stauner||Director||Buy||8,300||$3.03||$25,149.00||35,450|| |
|8/7/2013||Robert Kill||CEO||Buy||36,050||$2.77||$99,858.50||346,050|| |
|8/6/2013||Darin Hammers||VP||Buy||6,800||$2.82||$19,176.00||6,800|| |
Uroplasty (NASDAQ UPI) News Headlines
Uroplasty (NASDAQ:UPI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Uroplasty (NASDAQ:UPI) Income Statement, Balance Sheet and Cash Flow Statement
Uroplasty (NASDAQ UPI) Stock Chart for Sunday, February, 18, 2018